RxDoctor Payments Data

Jill Shelby, NP

Psychiatric/Mental Health · Lafayette, INNPI 1467482570

Payments from drug & device makers

$992in general payments, 2019–2025

Across 43 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$400
  • E.r. Squibb & Sons, L.L.C.$183
  • Alkermes, Inc.$112
  • Axsome Therapeutics, Inc.$108
  • Otsuka America Pharmaceutical, Inc.$86
  • Amgen$47
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$97899%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$992 in reported general payments places this provider in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$61,751
Medicare patients
281
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa22$466,483
Humira(Cf) PenAdalimumab12$79,495
OtezlaApremilast12$56,153
Lurasidone Hcl55$3,240
Ketoconazole154$2,861
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$2,002
Metronidazole19$1,126
Doxycycline Monohydrate19$1,098
Betamethasone Dipropionate27$888
Doxycycline Hyclate54$563
Buspirone Hcl67$551
Triamcinolone Acetonide54$368
Duloxetine Hcl31$357
Hydroxyzine Hcl16$331
Venlafaxine Hcl ErVenlafaxine Hcl17$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$47$56,15312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →